Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 13/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168818 | 0.92 | UGCG (0.39) | UGCGMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL2168095 | 0.89 | UGCG (0.45) | UGCGHRH3 | |
| SCHEMBL2170033 | 0.87 | UGCG (0.42) | UGCGMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL2167612 | 0.87 | GAA (0.36) | UGCGMCHR1CYP2D6MAPT | |
| SCHEMBL2167768 | 0.86 | UGCG (0.42) | UGCGMCHR1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL2166965 | 0.85 | KCNQ2 (0.35) | UGCGALDH1A1GLA | |
| SCHEMBL2169097 | 0.85 | UGCG (0.40) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL14655749 | 0.85 | UGCG (0.36) | UGCG | |
| SCHEMBL2167861 | 0.85 | UGCG (0.36) | UGCGMEN1KMT2A | |
| SCHEMBL2168497 | 0.84 | CHRNA7 (0.35) | UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2016-11-24 | — | — | US | disclosed |
| US-9481671-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9272996-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2015-08-13 | — | — | US | disclosed |
| US-8940776-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8389517-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | UGCG 27/4885HRH3 3744/4885MCHR1 4006/4885 |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | UGCG 6/4885HRH3 3628/4885MCHR1 4110/4885 |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | UGCG 14/4885HRH3 4677/4885MCHR1 4574/4885 |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | UGCG 6/4885HRH3 3628/4885MCHR1 4110/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | UGCG 14/4885HRH3 4677/4885MCHR1 4574/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | UGCG 27/4885HRH3 3744/4885MCHR1 4006/4885 |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GBA1, UGCG, GBA2 | UGCG 2/4885HRH3 3772/4885MCHR1 3337/4885 |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | UGCG 6/4885HRH3 3628/4885MCHR1 4110/4885 |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | UGCG 2/4885HRH3 3772/4885MCHR1 3337/4885 |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | UGCG 14/4885HRH3 4677/4885MCHR1 4574/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | UGCG 27/4885HRH3 3744/4885MCHR1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.